G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 100 filers reported holding G1 THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 17.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $158,000 | -25.5% | 20,759 | 0.0% | 0.00% | – |
| Q4 2021 | $212,000 | -21.2% | 20,759 | +3.7% | 0.00% | -100.0% |
| Q3 2021 | $269,000 | -38.7% | 20,012 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $439,000 | +33.0% | 20,012 | +46.0% | 0.00% | 0.0% |
| Q1 2021 | $330,000 | +36.4% | 13,708 | +1.9% | 0.00% | – |
| Q4 2020 | $242,000 | +56.1% | 13,448 | 0.0% | 0.00% | – |
| Q3 2020 | $155,000 | -51.6% | 13,448 | +1.8% | 0.00% | -100.0% |
| Q2 2020 | $320,000 | +119.2% | 13,208 | 0.0% | 0.00% | – |
| Q1 2020 | $146,000 | -58.2% | 13,208 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $349,000 | +17.9% | 13,208 | +1.6% | 0.00% | 0.0% |
| Q3 2019 | $296,000 | -25.8% | 12,998 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $399,000 | -11.1% | 12,998 | +51.5% | 0.00% | 0.0% |
| Q3 2018 | $449,000 | +41.6% | 8,581 | +17.5% | 0.00% | 0.0% |
| Q2 2018 | $317,000 | – | 7,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |